Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: Study design and baseline characteristics

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 9, 2009, Pages 818-829

  Phillips, Lisa J ^a   Nelson, Barnaby ^a,b   Yuen, Hok Pan ^a,b   Francey, Shona M ^a,b   Simmons, Magenta ^a,b   Stanford, Carrie ^a,b   Ross, Margaret ^a,b   Kelly, Daniel ^a,b   Baker, Kathryn ^b   Conus, Philippe ^c   Amminger, Paul ^a,b   Trumpler, Francois ^d   Yun, Yang ^a,b   Lim, Michelle ^a   McNab, Catharine ^b   Yung, Alison R ^a,b   McGorry, Patrick D ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Clinical trial; Early intervention; Psychotic disorders; Schizophrenia

Indexed keywords

PLACEBO; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROPROTECTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOCIAL SUPPORT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; COGNITIVE THERAPY; COUNSELING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PATIENT SELECTION; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REFUSAL TO PARTICIPATE; RESEARCH DESIGN; RISK; RISPERIDONE;

EID: 69449108408     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670903107625     Document Type: Article

References (50)

1. Sullivan HS. The onset of schizophre nia. Am J Psychiatry 1927 reprinted 1994; 151:135-139.
2. Perälä J, Suvisaari J, Saarni SI et al. Lifetime prevalence of psychotic and bipolar disorders in a general population. Arch Gen Psychiatry 2007; 64:19-28.
3. Lopez AD, Jamison DT, Mathers CD, Murray CJL, Ezzati M eds Global burden of disease and risk factors. New York NY: Oxford University Press, 2006.
4. Jablensky A. Epidemiology of schizop hrenia: The global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250:274-285.
5. Craig TK, Garety P, Power P et al. The Lambeth Early Onset (LEO) Team: Randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 2004; 329:1067.
6. Garety PA, Craig TK, Dunn G et al. Specialised care for early psychosis: Symptoms, social functioning and patient satisfaction: randomised controlled trial. Br J Psychiatry 2006; 188:37-45.
7. Petersen L, Jeppesen P, Thorup A et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005; 331:602.
8. Larsen TK, Melle I, Auestad B et al. Early detection of firstepisode psychosis: The effect on 1-year outcome. Schizophr Bull 2006; 32:758-764.
9. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med 2003; 33:97-110.
10. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Arch Gen Psychiatry 2005; 62:975-983.
11. McGorry PD. Value of early intervention in psychosis. Br J Psychiatry 2004; 185:172.
12. Cannon TD, Cornblatt B, McGorry PD. The empirical status of the Ultra High-Risk (Prodromal) Research Paradigm. Schizophr Bull 2007; 33:661-664.
13. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychos is. Schizophr Bull 1996; 22:283-303.
14. Yung AR, Phillips LJ, McGorry PD. Treating schizophrenia in the prodromal phase. London: Taylor and Francis, 2004.
15. Yung AR, Phillips LJ, Yuen HP, McGorry PD, Francey SF, McFarlane CA. Psychosis prediction: 12 month follow-up of a high risk ('prodromal') group. Schizophr Res 2003; 60: 21-32.
16. Gottesman II, Shields J. Schizophrenia: The epigenetic puzzle. Cambridge: Cambridge University Press, 1982.
17. Cadenhead K. Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics and the identification of the schizophrenia prodrome. Psychiatr Clin North Am 2002; 25:837-853.
18. Larsen TK. The transition from the premorbid period to psychosis: How can it be described? Acta Psychiatr Scand Suppl 2002; 106:10-11.
19. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res 2004; 71:227-237.
20. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Symptoms: Preliminary evidence of interrater and predictive validity. Am J Psychiatry 2002; 159:863-865.
21. Yung AR, Yuen HP, Berger G et al. Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull 2007; 33:673-681.
22. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophr Bull 2003; 29: 633-651.
23. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928.
24. Phillips LJ, McGorry PD, Yuen HP et al. Medium term follow-up of a randomized controlled trial of inter ventions for young people at ultra high risk of psychos is. Schizophr Res 2007; 96:25-33.
25. McGlashan TH, Zipursky RB, Perkins D et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophr Res 2003; 61:7-18.
26. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:790-799.
27. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychos is in people at ultra-high risk. Br J Psychiatry 2004; 185:291-297.
28. Morrison AP, French P, Parker S et al. Three year follow-up of a randomised controlled trial of cognitive therapy for the prevention of psychos is in people at ultra-high risk. Schizophr Bull 2007; 33:682-687.
29. Phillips LJ, Leicester SB, O'Dwyer LE et al. The PACE Clinic: identification and management of young people at 'ultra' high risk of psychosis. J Psychiatr Pract 2002; 8: 255-269.
30. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: The Comprehensive Assessment of At Risk Mental States (CAARMS). Aust N Z J Psychiatry 2005; 39:964-971.
31. Phillips LJ, Francey SM. Changing PACE: Psychological interventions in the pre-psychotic phase. In: McGorry P, Gleeson J, eds. Psychological interventions in early psychosis: A practical treatment handbook. Chichester: John Wiley and Sons, 2004:23-40.
32. Zubin J, Spring B. Vulnerability: A new view of schizophrenia. J Abnorm Psychol 1977; 86:103-126.
33. Francey SM, Jackson HJ. Assessment and developing a formulation. In: Addington J, Francey SM, Morrison AP, eds. Working with people at high risk of developing psychosis: A treatment manual. Chichester: John Wiley and Sons, 2006: 25-40.
34. Chadwick P, Birchwood M, Trower P. Cognitive therapy for delusions, voices and paranoia. Chichester: John Wiley and Sons, 1996.
35. Fowler D, Garety P, Kuipers E. Cognitive behaviour therapy for psychosis: Theory and practice. Chichester: Wiley, 1995.
36. Haddock G, Tarrier N, Spaulding W, Yusupoff L, Kinney C, McCarthy E. Individual cognitive-behavior therapy in the treatment of hallucina tions and delusions: A review. Clin Psychol Rev 1998; 18:821-838.
37. Kingdon D, Turkington D. Cognitive-behavioural therapy for schizophrenia. Hove, UK: Lawrence Erlbaum, 1994.
38. Lewis SW, Tarrier N, Haddock G et al. A randomised controlled trial of cognitive behavior therapy in early schizophrenia. Schizophr Res 2001; 49 (Suppl):263.
39. Young JA, Beck AT. Cognitive Therapy Scale: Rating manual. Philadelphia, PA: Centre for Cognitive Therapy, University of Pennsylvania, 1980.
40. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 76:85-94.
41. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders,Research Version, Patient Edition. New York: Biometrics Research, New York State Psychiatric Institute, 2002.
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (text revision, fourth edn). Washington, DC: American Psychiatric Association, 2000.
43. Heinrichs DW, Hanlon TE, Carpenter WJ. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-398.
44. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812.
45. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1983.
46. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-61.
47. Mrazek PJ, Haggerty RJ. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington, DC: National Academy Press, 1994.
48. Sensky T, Turkington D, Kingdon D et al. A randomised controlled trial of cognitive-behavioural therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000; 57:165-172.
49. Bendall S, Jackson HJ, Killackey E et al. The credibility and acceptability of befriending as a control therapy in a randomized controlled trial of cognitive behaviour therapy for acute first episode psychosis. Behav Cogn Psychother 2006; 34:277-291.
50. Double DB. Future of psychotherapy in the NHS: Control groups play important part. BMJ 2004; 329:514.